American College Of Medical Toxicology, Inc.

American College of Medical Toxicology, Inc. (ACMT), a non-profit organization based in Paradise Valley, Arizona, serves as a specialized provider of medical toxicology expertise, research services, and data analytics to federal health agencies. The organization operates as a tax-exempt corporate entity and maintains registration in the System for Award Management (SAM.gov) through June 2026. ACMT leverages its core competency in toxicology investigations, poison control expertise, and clinical research to support federal initiatives addressing public health challenges related to drug use, overdoses, medical product safety, and toxicological exposures.

Through federal contract awards, ACMT has provided comprehensive toxicology research, surveillance, and training services to multiple federal agencies without the use of set-aside designations. The organization holds a prime definitive contract with the Food and Drug Administration (FDA) valued at $2.71 million to characterize the clinical use, risks, benefits, and effectiveness of naloxone in reversing opioid overdoses in pre-hospital settings using qualitative and quantitative blood toxicology tests, with completion expected by September 2026. ACMT also serves as prime contractor on a $2.3 million definitive contract with the Centers for Disease Control and Prevention (CDC) providing access to its Toxicology Investigators Consortium (TOXIC) registry database for analyzing nonfatal drug overdose data, with a base period of one year and three optional one-year extensions ending in June 2027. Additionally, ACMT received a $565,000 delivery order from the FDA for near real-time surveillance of stimulants in the overdose crisis through its Drug Overdose Toxico-Surveillance (DOTS) Expansion program, and a $5.2 million delivery order from the FDA for toxic registry online access and COVID-19 pharmacovigilance support services extending through September 2027. The organization also delivered a $254,018 purchase order training contract with CDC Pittsburgh for the two-day "ACMT Agents of Opportunity Training" course. As a subcontractor, ACMT has supported Battelle Memorial Institute on multiple task orders related to chemical medical mitigation, medical toxicology support, and medical expert support for chemical agent response since January 2022.

Through federal grant programs, ACMT has served as both prime grantee and subgrantee on cooperative agreements and research grants focused on toxicology research, workforce development, and public health capacity building. As prime grantee, ACMT received a $400,000 cooperative agreement from the Executive Office of the President's Office of the National Drug Control Policy (ONDCP) under the Research and Data Analysis program (CFDA 95.007) to compare illicit drugs in the drug supply with those detected in biological specimens from emergency departments, supporting national drug policy research through September 2026. ACMT also holds a major cooperative agreement with the Centers for Disease Control and Prevention for a Medical Toxicologists Capacity Building Assistance Program spanning five years (August 2024 through July 2029) designed to strengthen the public health system by enhancing medical toxicologists' competencies in risk communication, risk assessment, emergency preparedness, and public health response to toxicological threats including substance use disorders, the opioid crisis, environmental exposures, and hazardous substances. As a subgrantee, ACMT has collaborated with the Icahn School of Medicine at Mount Sinai on multiple research projects utilizing its TOXIC registry to investigate opioid overdose patterns, drug exposures, and poisonings in emergency department settings, with subgrants dating from July 2022 through August 2024. ACMT has also served as subgrantee to the American Academy of Pediatrics on the Pediatric Environmental Health Specialty Unit (PEHSU) program, managing the PEHSU national website, e-classroom platform, and providing educational content related to environmental health threats and health disparities affecting children, with sub-awards from February 2022 through November 2023. Additionally, ACMT participated as subgrantee to the University of Massachusetts Medical School on "The Antidote Institute" grant (awarded June 2023) focused on advancing new toxicology investigators in drug abuse and translational research, with ACMT leadership providing co-investigator expertise, research design input, and leadership on diversity and inclusion initiatives.

ACMT holds a single-award Indefinite Delivery Contract (IDC) with the Food and Drug Administration valued at $16 million with a period of performance through September 2027. This contract vehicle supports ACMT's provision of toxic registry online access, COVID-19 and pharmacovigilance sub-registry support, and related toxicology data and research services to the FDA. Multiple task orders have been issued under this IDC, including the $565,000 Drug Overdose Toxico-Surveillance (DOTS) Expansion order focused on near real-time surveillance of stimulants in the overdose crisis and the $5.2 million toxic registry online access and COVID-19 pharmacovigilance support delivery order. Through this vehicle, the FDA leverages ACMT's specialized expertise in clinical research, poison control, and toxicology data analytics to enhance federal monitoring of stimulant drugs, adverse events, and public health surveillance related to drug use and overdoses. The IDC was awarded without set-aside designation, reflecting ACMT's competitive selection as the sole-source provider of these specialized services within the federal contracting landscape.